Skip to search boxSkip to navigationSkip to main content

SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview

  • Ali A. Rabaan(corresponding author)
    ,
  • Shamsah H. Al-Ahmed
    ,
  • Shafiul Haque
    ,
  • Ranjit Sah
    ,
  • Ruchi Tiwari
    ,
  • Yashpal Singh Malik
*Corresponding author for this work
  • Johns Hopkins Aramco Healthcare
    ,
  • Qatif Central Hospital
    ,
  • Jazan University
    ,
  • Tribhuvan University Teaching Hospital
    ,
  • Up Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU)
    ,
  • ICAR-Indian Veterinary Research Institute
Research Output:
Contribution to journal
Review article
Peer-review

Publication Information

Output type

Research Output:
Contribution to journal
Review article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 174-184 (11 pages)

Journal (Volume, Issue Number)

Infezioni in Medicina (Volume 28, Issue 2)

Publication milestones

  • Published - 2020

Publication status

Published - 2020

ISSN

1124-9390

Publication IDs

  • Scopus: 85083543972
  • PubMed: 32275259

Abstract

The recent outbreak of SARS-CoV-2 that started in Wu-han, China, has now spread to several other countries and is in its exponential phase of spread. Although less pathogenic than SARS-CoV, it has taken several lives and taken down the economies of many coun-tries. Before this outbreak, the most recent coronavi-rus outbreaks were the SARS-CoV and the MERS-CoV outbreaks that happened in China and Saudi Arabia, respectively. Since, the SARS-CoV-2 belongs to the same family as of SARS-CoV and MERS-CoV, they share several similarities. So, this review aims at un-derstanding the new scenario of SARS-CoV-2 outbreak and compares the epidemiology, clinical presentations, and the genetics of these coronaviruses. Studies re-veal that SARS-CoV-2 is very similar in structure and pathogenicity with SARS-CoV, but the most important structural protein, i.e., the spike protein (S), is slightly different in these viruses. The presence of a furin-like cleavage site in SARS-CoV-2 facilitates the S protein priming and might increase the efficiency of the spread of SARS-CoV-2 as compared to other beta coronaviruses. So, furin inhibitors can be targeted as potential drug therapies for SARS-CoV-2.

Publication metrics

Metrics

Scopus
Citations

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well